BioSpace News Archive

Ra Medical Systems, Inc. announces that it will report third quarter 2020 financial results and provide a business update after market close on Thursday, November 12, 2020.

Completed Rolling NDA Submissions for Both BCV Tablet and SuspensionFormulations as Medical Countermeasure for Smallpox

VYNE Therapeutics Inc. announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative diseases Company revamping its organization to focus on critical IW-6463 CNS program priorities; expects 2021 average cash use reduction of approximately 50% from Q3 2020 levels

– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues ; program updates planned for December 2020 – – Arvinas and Pfizer enter collaboration and supply agreement ; initiation of Phase 1b combination of ARV-471 and Ibrance ® e xpected in the f ourth q uarter of 2020 –

Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi Reported positive interim results from non-interventional study o f KT-474 (IRAK4 degrader) in HS patients and declared KT-413 (IRAKIMiD degrader) as a development candidate and initiated IND enabling activities

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the third quarter ended September 30, 2020, and provided a corporate update. “We are 28 days from our PDUFA date and we are ready to launch ORLADEYO to bring HA

Commercial Manufacturing Base Settled in Suzhou BioBAY for the Development of Pharmaceutical Industry

Hutchison China MediTech Limited announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be presented as a poster at the upcoming 62nd American Society of Hematology Annual Meeting and Exposition, taking place on December 5-8, 2020 virtually.

B.D. Tiner, DDS, MD, FACS, was introduced as the 103rd president of the American Association of Oral and Maxillofacial Surgeons during its virtual House of Delegates sessions in September.